COVID-19 First Generation Vaccines Should Halve the Risk of Infection

Dr. Amesh Adalja, a senior scholar with the Johns Hopkins Center for Health Security, reports that the first generation of COVID-19 vaccines will give people who have vaccinated a 50% lower chance of getting infected than somebody who hasn’t been vaccinated.

US Operation Warp Speed is giving billions to private pharma companies to try to get a widely deployed vaccine by January 2021. Operation Warp Speed’s goal is to produce and deliver 300 million doses of safe and effective vaccines with the initial doses available by January 2021.

Clinical trials are still taking enough time to gather the safety and effectiveness data needed for approval.

The first vaccines will also probably need two shots per person.

When Operation Warp Speed spends $1-2 billion to support vaccine manufacturing then the U.S. Government will own the resulting 100 million doses of vaccine and will have the option to acquire more.

March 30: HHS announced $456 million in funds for Johnson & Johnson’s (Janssen) candidate vaccine. Phase 1 clinical trials began in Belgium on July 24th and in the U.S on July 27th.

April-July Moderna has gotten $955 million and is now in Phase 3.

In August, $1.5 billion in funds to support the large-scale manufacturing and delivery of Moderna’s investigational vaccine candidate.

In May, HHS gave $1.2 billion in support for AstraZeneca’s candidate vaccine, developed in conjunction with the University of Oxford. This is also in Phase 3.

In July, HHS announced $1.6 billion in funds to support the large-scale manufacturing of Novavax’s vaccine candidate.

In July, HHS announced up to $1.95 billion in funds to Pfizer for the large-scale manufacturing and nationwide distribution of 100 million doses of their vaccine candidate.

In July, HHS gave $450 million in funds to support the large-scale manufacturing of Regeneron’s COVID-19 investigational anti-viral antibody treatment, REGN-COV2.

In July, $2 billion will be provided for the advanced development, including clinical trials and large scale manufacturing, of Sanofi and GlaxoSmithKline’s (GSK) investigational adjuvanted vaccine.

In August, $1 billion for the large-scale manufacturing and delivery of Johnson & Johnson’s investigational vaccine candidate.

SOURCES- Health and Human Services, UPI
Written By Brian Wang,